Generali Investments Management Co LLC Has $2.05 Million Position in Boston Scientific Corporation $BSX

Posted by George Bondi on Aug 11th, 2026

Boston Scientific logo Generali Investments Management Co LLC boosted its position in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 63.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 48,040 shares of the medical equipment provider’s stock after buying an additional 18,566 shares during the quarter. Generali Investments Management Co LLC’s holdings in Boston Scientific were worth $2,050,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Renaissance Group LLC bought a new stake in shares of Boston Scientific during the 4th quarter valued at $28,064,000. PensionDanmark Pensionsforsikringsaktieselskab boosted its position in shares of Boston Scientific by 9.9% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after purchasing an additional 28,961 shares during the last quarter. Meiji Yasuda America Inc bought a new position in shares of Boston Scientific in the 4th quarter worth $4,708,000. Harvest Portfolios Group Inc. grew its stake in shares of Boston Scientific by 6.1% during the fourth quarter. Harvest Portfolios Group Inc. now owns 597,341 shares of the medical equipment provider’s stock worth $56,956,000 after purchasing an additional 34,598 shares during the period. Finally, LBP AM SA grew its stake in shares of Boston Scientific by 8.4% during the fourth quarter. LBP AM SA now owns 434,393 shares of the medical equipment provider’s stock worth $41,419,000 after purchasing an additional 33,534 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Up 2.3%

Shares of Boston Scientific stock opened at $50.42 on Tuesday. The firm has a market cap of $73.07 billion, a PE ratio of 20.41, a P/E/G ratio of 1.08 and a beta of 0.56. The business’s 50 day simple moving average is $45.80 and its 200 day simple moving average is $60.25. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the business earned $0.75 EPS. The business’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its board has authorized a share buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

Several equities analysts have weighed in on BSX shares. Bank of America cut their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Raymond James Financial reaffirmed an “outperform” rating and issued a $57.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Finally, Needham & Company LLC decreased their price objective on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, July 8th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $71.62.

View Our Latest Research Report on Boston Scientific

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director David C. Habiger acquired 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This represents a 19.35% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Michael F. Mahoney acquired 186,240 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 204,322 shares of company stock worth $9,939,221 in the last three months. 0.34% of the stock is currently owned by company insiders.

About Boston Scientific

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.